Search

Displaying results 2851 - 2860 of 10000 in total
  1. Drug

    Avacopan

    go.drugbank.com/drugs/DB15011
    ApprovedInvestigational

    [L39850] Avacopan was approved by Health Canada on April 20, 2022.[L41650] … [A240254, A240259, A240264, A240269] Avacopan (formerly CCX168) is an allosteric C5aR antagonist indicated for use in AAV.

  2. Drug

    Tilidine

    go.drugbank.com/drugs/DB13787
    Investigational

    Mixtures: TILIDIN HEXAL COMP D-PUMPE, VALORON N RETARD 200/16MG
  3. Drug

    Capivasertib

    go.drugbank.com/drugs/DB12218
    ApprovedInvestigational

    Although endocrine-based therapy is the first line of treatment, resistance eventually emerges, leaving chemotherapy the only but often ineffective treatment left. … metastatic breast cancer with one or more alterations in PIK3CA/AKT1/PTEN gene(s) in combination with [fulvestrant].

  4. Drug

    COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection

    go.drugbank.com/drugs/DB15845
    Experimental

    As of July 2020, Medicine Invention Design, Inc. is sponsoring a small, controlled clinical trial for the COVID-19 AP TP Vaccine for ‘proof of concept.’ … The vaccine utilizes granulocyte macrophage-colony stimulating factor (GM-CSF), a cytokine known to enhance vaccine efficacy through prolongation of humoral and cell immunity.

    Synonyms: COVID-19 Therapeutic Vaccine - Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection
  5. Drug

    Landiolol

    go.drugbank.com/drugs/DB12212
    ApprovedInvestigational

    [A264733,A264738] First approved in Japan in 2002 [A264758] for the treatment of intraoperative tachyarrhythmias,[A264733] landiolol was approved in Canada in April 2024 [L51938] and in the US in November … [A264733] Compared to other beta-blockers, landiolol possesses unique pharmacodynamic and pharmacokinetic properties, in that it has a rapid onset and short duration of action, and has a greater affinity

  6. Drug

    Vusolimogene oderparepvec

    go.drugbank.com/drugs/DB23008
    ApprovedInvestigational

    on anti-PD-1 therapy. … [L64061] The virus is engineered to express a fusogenic glycoprotein derived from gibbon ape leukemia virus (GALV-GP-R–) and human granulocyte-macrophage colony-stimulating factor (GM-CSF), and has its

  7. Drug

    Nicoboxil

    go.drugbank.com/drugs/DB12911
    ApprovedWithdrawn

    Nicoboxil has been investigated for the treatment of Acute Low Back Pain, where it is typically considered an effective and safe therapeutic option. … Such combination topical analgesics are only available for purchase and use (for humans) in some parts of Europe and Asia, like Germany and Australia [F11, F16].

    Mixtures: Nonivamid + Nicoboxil Zentiva 4 mg/g + 25 mg/g Salbe
  8. Drug

    Potassium guaiacolsulfonate

    go.drugbank.com/drugs/DB13735
    ApprovedWithdrawn

    Guaiacolsulfonate is an aromatic sulfonic acid. Potassium guaiacolsulfonate salt is an expectorant that thins the mucus in the lungs and reduces chest congestion.

    Mixtures: ARTU 100 ML SURUP, ANTIBEKSIN SURUP, 100 ML
  9. Drug

    Paritaprevir

    go.drugbank.com/drugs/DB09297
    ApprovedInvestigational

    In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Paritaprevir as a first line … Depending on the genotype, Paritaprevir is often used in combination with other antivirals such as [DB09296], [DB09183], [DB00503], and [DB00811], with the intent to cure, or achieve a sustained virologic

    Synonyms: (2R,6S,12Z,13aR,14aR,16aS)-N-(cyclopropanesulfonyl)-6-[(5-methylpyrazine-2-carbonyl)amino]-5,16-dioxo-2-[(phenanthridin-6-yl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrroloMixtures: VIEKIRAX 12.5 MG/75 MG/50 MG FILM KAPLI TABLET ,56 TABLET
  10. Drug

    Maftivimab

    go.drugbank.com/drugs/DB15899
    ApprovedInvestigational

    INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320] … [A221825] Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high